[vc_row][vc_column][ultimate_exp_section title=”What should I avoid while taking Upadacitinib?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left” icon_margin=”margin-left:100px;”][vc_column_text css=””]Ans: Do not consume grapefruit or grapefruit-containing products while taking Upadacitinib, as they may raise the risk of side effects.[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”What are other possible side effects of Upadacitinib?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]Ans: Upadacitinib may cause side effects such as upper respiratory infections, nausea, cough, headache, and increased cholesterol. Serious risks include infections, blood clots, liver issues, low blood counts, certain cancers, and cardiovascular events. Regular monitoring is recommended.[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”How should I take Upadacitinib?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]Ans: Upadacitinib tablets are taken once daily, with or without food. Swallow the tablet whole, do not split, crush, or chew it. Take it exactly as prescribed by your healthcare provider. The tablets are available in 15 mg extended-release strengths.[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”How expensive is Upadacitinib?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]No. As a commitment to patient affordability, Everest Pharmaceuticals Ltd. introduces Upajak, the global generic version of Resmetirom (RINVOQ). This medication is now accessible to patients worldwide at a more affordable price. Contact us to learn more about availability and purchasing options.[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”Is Upadacitinib like a steroid?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]No. It is a specific JAK inhibitor which is used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, atopic dermatitis, ulcerative colitis, Crohn’s disease, and giant cell arteritis, offering targeted therapy across a range of inflammatory and autoimmune conditions.[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”Is Upadacitinib a chemotherapy?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]No, Rinvoq (generic name: Upadacitinib) is classified as a Janus kinase (JAK) inhibitor and disease-modifying antirheumatic drug (DMARD).[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”Can Upadacitinib be stopped?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]You should not stop taking Upadacitinib unless your doctor recommends it.[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”Is Upadacitinib better than methotrexate?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]A comparison between Methotrexate and Upadacitinib shows that Methotrexate has an average rating of 6.5 out of 10 based on 337 reviews on Drugs.com, with 53% of users reporting a positive effect and 24% reporting a negative one. Upadacitinib holds a slightly higher average rating of 7.0 out of 10 from 230 reviews on the same platform.[/vc_column_text][/ultimate_exp_section][ultimate_exp_section title=”Is Upadacitinib better than Humira/Adalimumab ?” text_color=”#000000″ text_hovercolor=”#ffffff” bghovercolor=”#1d9aba” title_active=”#ffffff” title_active_bg=”#1d9aba” cnt_bg_color=”#1d9aba” icon=”icomoon-the7-font-the7-arrow-05″ new_icon=”icomoon-the7-font-the7-arrow-04″ icon_align=”right” icon_size=”20″ icon_color=”#1d9aba” icon_hover_color=”#ffffff” icon_active_color=”#ffffff” title_alignment=”left”][vc_column_text css=””]For rheumatoid arthritis, head-to-head clinical trials (such as SELECT-COMPARE) have shown that Upadacitinib demonstrated superior efficacy in improving symptoms and physical function compared to Humira (Adalimumab) when both were used alongside methotrexate.[/vc_column_text][/ultimate_exp_section][/vc_column][/vc_row]